MAP2K1 and colorectal cancer: In advanced colorectal cancer, all the patients with MAP2K1 mutation treated with anti-EGFR, anti-EGFR combined with MEK and BRAF inhibitors, or anti-EGFR combined with ERK inhibitors, showed disease progression, where the MAP2K1 mutation was associated with poor response to targeted therapy (21).